Status:
UNKNOWN
Clinical Trials to Assess the Efficacy and Safety of HLIM
Lead Sponsor:
SamA Pharmaceutical Co., Ltd
Conditions:
Acute Upper Respiratory Tract Infection
Acute Bronchitis
Eligibility:
All Genders
2-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the efficacy and safety of HLIM
Detailed Description
A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial.
Eligibility Criteria
Inclusion
- Age between 2 and 75
- Weight more than 11.5 kg
Exclusion
- Has a history of hypersensitivity to IP ingredients
- Hypertension or Diabetes
- Smoking more than 20 pack-years
Key Trial Info
Start Date :
November 29 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2019
Estimated Enrollment :
487 Patients enrolled
Trial Details
Trial ID
NCT03827590
Start Date
November 29 2018
End Date
October 31 2019
Last Update
February 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Guro Hospital
Seoul, Guro-gu, South Korea, 08308